Bayer to commercialise Daré’s monthly contraceptive Ovaprene in US

This article was originally published here

Ovaprene is Daré’s investigational hormone-free monthly vaginal contraceptive, which is under clinical development to prevent pregnancy. Under the exclusive licence agreement, Bayer will commercialise Ovaprene after it is

The post Bayer to commercialise Daré’s monthly contraceptive Ovaprene in US appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply